Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
InMode ( (INMD) ) has issued an announcement.
On May 15, 2025, InMode Ltd. held its Annual General Meeting of Shareholders where several key proposals were approved. These included the re-election of directors Moshe Mizrahy and Michael Kreindel, the re-appointment of Kesselman & Kesselman as independent auditors, and the granting of restricted share units to certain directors. The meeting was properly convened with a quorum present, and all proposals were passed according to the requirements of Israeli Companies Law.
The most recent analyst rating on (INMD) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on InMode stock, see the INMD Stock Forecast page.
Spark’s Take on INMD Stock
According to Spark, TipRanks’ AI Analyst, INMD is a Outperform.
InMode’s overall stock score of 70 reflects a mix of strong financial performance and undervaluation, tempered by current bearish technical indicators and cautious earnings guidance. The company’s robust balance sheet and profitability are significant strengths, supporting long-term resilience. However, the short-term challenges, including declining revenue and reduced margins, along with bearish market momentum, present risks that investors should consider.
To see Spark’s full report on INMD stock, click here.
More about InMode
InMode Ltd. operates in the medical technology industry, focusing on developing and providing innovative minimally invasive aesthetic solutions. The company’s primary products include radiofrequency-based devices used for a variety of aesthetic and medical procedures.
Average Trading Volume: 1,443,172
Technical Sentiment Signal: Sell
Current Market Cap: $1.02B
For a thorough assessment of INMD stock, go to TipRanks’ Stock Analysis page.